(Q46135283)

19 December 2017

title

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma (English)

1 reference

19 December 2017

author name string

Sadahisa Ogasawara

1

1 reference

19 December 2017

Fumihiko Kanai

2

1 reference

19 December 2017

Shuntaro Obi

3

1 reference

19 December 2017

Shinpei Sato

4

1 reference

19 December 2017

Taketo Yamaguchi

5

1 reference

19 December 2017

Ryosaku Azemoto

6

1 reference

19 December 2017

Hideaki Mizumoto

7

1 reference

19 December 2017

Youhei Koushima

8

1 reference

19 December 2017

Naoki Morimoto

9

1 reference

19 December 2017

Nobuto Hirata

10

1 reference

19 December 2017

Takeshi Toriyabe

11

1 reference

19 December 2017

Yusuke Shinozaki

12

1 reference

19 December 2017

Yoshihiko Ooka

13

1 reference

19 December 2017

Rintaro Mikata

14

1 reference

19 December 2017

Tetsuhiro Chiba

15

1 reference

19 December 2017

Shinichiro Okabe

16

1 reference

19 December 2017

Fumio Imazeki

17

1 reference

19 December 2017

Masaharu Yoshikawa

18

1 reference

19 December 2017

Osamu Yokosuka

19

1 reference

19 December 2017

language of work or name

1 reference

22 January 2011

1 reference

19 December 2017

published in

Hepatology international

1 reference

19 December 2017

volume

5

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

850-856

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s12072-010-9249-4

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Hepatocellular carcinoma development in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

International trends and patterns of primary liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Hepatocellular carcinoma in the Asia pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-010-9249-4

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan

21 January 2018

1 reference

12 December 2020

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

1 reference

12 December 2020

Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study

1 reference

12 December 2020

Epidemiology of hepatocellular carcinoma in Japan

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S12072-010-9249-4

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

21484134

1 reference

19 December 2017